Resource Center

In 2021, Health Canada authorized the use of flibanserin in postmenopausal women, a move that Sprout cited as an important step toward the current FDA action.

• Global availability varies; approved in the US, Canada, and some other countries.
• Not approved in the European Union by the EMA as of current knowledge.
• Different brand names may be used in countries where it is marketed.
• Importing for personal use from other countries carries risks and is often illegal.
• Counterfeit versions of the medication are a potential danger.
• Patients should only obtain it from a certified, licensed pharmacy.
• Telemedicine may be used for consultations but REMS requirements still apply.
• The future of flibanserin may involve generic competition reducing cost.
• Research into its potential effects on other conditions (e.g., depression) is limited.

With the expanded US indication, Addyi is now approved for women younger than 65 years,

In case of emergency/overdose

Addyi was the first drug approved to treat FSIAD. Addyi is designed for premenopausal people, and is available as a pill. A person takes this drug daily before bed, even if they do not intend to have sex that day. It can take no more than 8 weeks to see an increase in sexual desire, though some people experience the effects much sooner. The FDA states that Vyleesi medication can treat FSIAD in premenopausal females.

Concomitant Strong or Moderate CYP3A4 Inhibitor Use

A person injects it into their thigh or stomach at least 45 minutes before having sex. The effects can last for up to 24 hours. People should not use the drug more than eight times per month. The table below compares Vyleesi and Addyi: Viagra is not FDA approved for use in females. To understand why, it can help to understand what Viagra was designed to do in the male body. making it the first and only FDA-approved pharmacologic therapy for HSDD across this broader age range.

Sprout Pharmaceuticals stated that Addyi has been prescribed by more than 30,000 US health care professionals to date.

if she’s saying these things, it may be hsdd

Vyleesi (bremelanotide) and Addyi (flibanserin) can help treat female sexual interest/arousal disorder (FSIAD) in premenopausal people. The FDA has not approved Viagra for use cenforce 100mg tablet in females. The FDA also advises against taking over-the-counter supplements that are marketed to boost libido. Medication may not treat all causes of low sexual desire. A person can contact a doctor for advice on suitable medications and other ways to help improve their libido.

How can I get more information about Addyi?

The FDA approved flibanserin for HSDD in women younger than 65 years, expanding access to the first nonhormonal therapy for low sexual desire. The FDA has approved Addyi (flibanserin 100 mg) for the treatment of hypoactive sexual desire disorder (HSDD) in women younger than 65 years, according to an announcement from Sprout Pharmaceuticals. The decision expands the drug’s original indication and represents the first FDA approval specifically extending pharmacologic treatment options for postmenopausal women with HSDD. HSDD is characterized by a persistent lack of sexual interest or desire that causes distress and is not better explained by another medical or psychiatric condition. It is considered the most common form of sexual dysfunction in women, with estimates suggesting that approximately 40% of women experience symptoms consistent with low sexual desire at some point in their lives. The company emphasized that appropriate patient selection and counseling remain essential and that patients should consult with their physicians to determine whether treatment is appropriate.

Mary Claire Haver, MD, an obstetrician-gynecologist and menopause specialist, also emphasized the broader clinical context of the approval.

Microcircuits and Sexual Interest and Desire

Vyleesi and Addyi treat FSIAD in premenopausal people. No research has tested the drug in people during or after menopause. The medications may be beneficial for premenopausal people who: Factors that are lined with a reduced sex drive in females include: certain health conditions, such as diabetes and heart disease The FDA-approved drugs for FSIAD can have the following side effects. The side effects of Addyi can include: those who have consumed alcohol in the last 2 hours The drug can cause severe low blood pressure and fainting in people who take it with alcohol or who have liver conditions. irritation or a rash at the injection site darkening of the skin, resulting in dark spots called hyperpigmentation on the gums, face and breasts Vyleesi may reduce the efficiency of oral medications due to slower emptying of the gastric system.

Pediatric Precautions

It can also make drugs containing naltrexone to treat alcohol and opioid addiction less effective, so anyone taking a drug that contains naltrexone should avoid Vyleesi. Like other drugs, Vyleesi and Addyi can cause allergic reactions. Seek immediate medical help if symptoms of an allergic reaction or anaphylaxis occur. A person should speak with a doctor before taking any supplements to boost libido. The doctor can advise on the suitabilty of the products, and they may recommend medications such as Addyi and Vyleesi. “Menopause does not mark the end of a woman’s sexuality, but for too long, medicine has treated it that way,” Haver said. “This FDA approval is a long-overdue recognition that postmenopausal women deserve evidence-based treatment options for low sexual desire.

• Clinical trials excluded women with many comorbidities (e.g., unstable medical conditions).
• Real-world effectiveness in broader populations may differ from trial results.
• Patient satisfaction with treatment can vary widely.
• Some women report significant improvement in sexual desire and distress.
• Others discontinue due to side effects or lack of meaningful benefit.
• Adherence to daily dosing is a challenge for some patients.
• The bedtime dosing schedule is intended to mitigate side effects like dizziness.
• Taking it with a high-fat meal can increase absorption and side effect risk.
• Should be taken on an empty stomach, at least 2 hours after a high-fat meal.

Expanding Addyi’s approval is historic in validating women’s experiences and ensuring that millions of women suffering have real choices when

it comes to their sexual health.” Historic first in women's sexual health: FDA grants approval for Addyi (flibanserin) in postmenopausal women.

Desire Starts in the Brain...

It may not cover all possible information. If you have questions about this medicine, talk to your doctor, pharmacist, or health care provider. Sign up for our Health Essentials emails for expert guidance on nutrition, fitness, sleep, skin care and more. Note: Introduction and Additional Common Questions written and medically approved by Cleveland Clinic professionals. In the United States, two drugs have been approved to treat female sexual interest/arousal disorder (FSIAD): Vyleesi (bremelanotide) and Addyi (flibanserin).

What are the most common side effects of Addyi?

Some people may refer to these as “Viagra for females.” The Food and Drug Administration (FDA) have approved two drugs — flibanserin (Addyi) and bremelanotide (Vyleesi) — to address low desire or arousal in females. However, both are approved for use only in people who have not yet entered menopause. This article describes the FDA-approved medications for low libido in females, including how they work and the possible side effects. This article will use the terms “male,” “female,” or both to refer to sex assigned at birth. The FDA has approved two drugs to address FSIAD: Vyleesi (bremelanotide) and Addyi (flibanserin). aDepartment of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh bDepartment of Endocrinology, North East Medical College and Hospital, Sylhet,

Why is this medication prescribed?

Clinicians who specialize in sexual medicine and menopause care have described the expanded approval as an important step for patients who previously lacked FDA-approved treatment options. Rachel Rubin, MD, a urologist and sexual medicine specialist, highlighted the clinical implications for postmenopausal patients. “I was in the room a decade ago when Addyi became the historic first for women’s sexual health, and I have been waiting for this moment ever since,” Rubin said. “So many of my postmenopausal patients have carried the weight of frustrating low sexual desire with no FDA-approved option to turn to. It’s a critical acknowledgment that their pleasure, their well-being, and their quality of life matter—and that science-backed care should be available to every woman, at every stage of her life.” International regulatory decisions preceded the US approval. Bangladesh cDepartment of Medicine, Army Medical College Cumilla, Cumilla, Bangladesh dDepartment of Gyne & Obs, Khaliajuri Upazila Health Complex,

Metrics & Citations

Despite its prevalence, treatment options have historically been limited, particularly for postmenopausal women. “This milestone reflects a decade of persistent work with the FDA to fundamentally change how women’s sexual health is understood and prioritized,” said Cindy Eckert, founder and CEO of Sprout Pharmaceuticals. “Over the years, we’ve pushed for the science to speak louder than the stigma—and today’s approval shows how far we’ve come. I want to congratulate the FDA for recognizing what millions of women have long deserved: equitable, science-backed care at every stage of life.” Addyi was initially approved by the FDA in 2015 for the treatment of HSDD in premenopausal women. The medication is a nonhormonal, centrally acting agent that modulates key neurotransmitters involved in sexual response.

Related Pages

Since its original approval, its safety and efficacy profile has been evaluated in extensive clinical development programs, which Sprout described as the largest and most rigorous clinical trials conducted in women’s sexual health. The current approval follows the FDA’s decision earlier this year to grant priority review status to the expanded indication. Priority review is reserved for therapies that may provide significant improvements in the treatment of serious conditions or address unmet medical needs. According to the company, the designation and subsequent approval reflect increasing regulatory attention to gaps in women’s health care. “This is a major shift in expanding awareness and access to treatment for HSDD—a condition that is both common and profoundly undertreated—and we’re grateful that the FDA has acknowledged the importance of closing this gap in women’s sexual health care,” Eckert added. Netrokona, Bangladesh eDepartment of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, India fDepartment

What is Addyi (flibanserin)?

Usually, after sexual stimulation in a male, there is a release of nitric oxide, which increases levels of a regulatory agent in cells called cyclic guanosine monophosphate (cGMP). This increase in cGMP causes smooth muscle relaxation, and it leads to increased blood flow to the penis, resulting in an erection. In males, an erection goes down when an enzyme called phosphodiesterase type 5 (PDE-5) breaks down. Anyone who would like to try Viagra should ask a medical professional, who may prescribe the drug off-label. Vyleesi targets melanocortin receptors, which are linked to sexual function.

Generic Name

The drug modulates the brain pathways involved in sexual response. After 3 days of taking the medication, there is a steady level of the drug in the body. However, some people do not metabolize CYP2C19, an enzyme protein, effectively, and this can cause levels of the drug to build up, resulting in side effects. Vyleesi lasts around 2.7 hours, and the average time it takes to clear the body is 6.5 hours. The drug may slow how fast the body can process other medication. of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh gDepartment of Endocrinology, CEDAR Superspeciality Healthcare, Dwarka, New Delhi, India.

• Flibanserin, a serotonin receptor modulator, was initially investigated for depression.
• Its approval marked a historic moment in treating female sexual dysfunction.
• The medication's side effects necessitate careful patient education.
• Efficacy is often supported by patient-reported improvements in desire.
• It does not function as an aphrodisiac but affects brain chemistry.
• Flibanserin therapy requires adherence to dosing instructions.
• Women with low libido due to other health issues may not benefit from it.
• Its role is to complement behavioral or psychological therapy if needed.
• Research continues into better options for treating female hypoactive sexual desire.